

II/2010

QUARTERLY REPORT



		Q1-2/2010	Q1-2/2009	Change
Sales	Million EUR	52.9	52.4	1%
Return on revenue before tax	%	18%	14%	30%
EBITDA	Million EUR	13.9	11.3	23%
EBIT	Million EUR	10.0	7.8	28%
EBT	Million EUR	9.4	7.2	32%
Net income/loss before other shareholders' interests	Million EUR	5.9	5,8	1%
Profit	Million EUR	5.1	4.0	29%
Earnings per share (basic)	EUR	0.99	1.08	-9%
Operational cash flow	Million EUR	5.6	6.5	-14%
Depreciation and amortization on non-current assets	Million EUR	3.9	3.5	11%
Staff as of June 30	Persons	534	524	2%

Business development of the Eckert & Ziegler Group

Robust sales and highest quarterly profit

The Eckert & Ziegler Group equaled the sales level of prior quarters and recorded sales of EUR 27.2 million in the second quarter of 2010 (average per quarter 2009: EUR 25.3 million). Compared to the second quarter of 2009, net income after tax and minority interests increased by 44% to EUR 2.6 million. This means that the past quarter recorded the highest profit in the history of the company. Despite a 38% increase in the number of shares compared to the previous year's quarter, the income per share was increased by 4% to EUR 0.50/share.

In the first half of 2010, sales of EUR 52.9 million were achieved, an increase of EUR 0.5 million or 1% over the same period the previous year. Over the same period, the net income after tax and minority interests increased by EUR 1.2 million, or 29%, to EUR 5.1 million. However, since the number of shares increased by 42%, the earnings per share fell by 8% to EUR 0.99/share.

In order to correctly assess the results of the first half of 2010 compared to 2009, the following sections refer to the average quarterly figures of 2009 excluding special effects. This levels out effects from the integration of Nuclitec during the year and from the Russian project of the Therapy segment, for example.

Once again, the most successful segment was the Industry segment, which we have renamed "Isotope Products" going forward in order to bring it in line with the company names of the operating subsidiaries. For comparison purposes, in 2010 the following explanations once again add sales and income from the new Environmental Services segment to the Isotope Products segment, in which the values were still included in 2009.

Revenue increased by 9%, the unadjusted margin by 25% and the EBIT by 65%. The successful integration of Nuclitec continues. The synergies will become more obvious once restructuring expenses no longer apply. Compared to the first half of 2009, the segment was also able to report another increase in sales in the area of industrial components.

Environmental Services, which relate to taking back, reprocessing, recycling and disposal of low level radioactive waste, are included in the notes above on the Isotope Products segment for comparison purposes. No new business was expected here in the first half of 2010, and with EUR 2.7 million in sales and expenses for preparations for new business that led to a small loss of EUR 0.1 million, this area developed within the framework of expectations. The annual sales target of the existing business (taking back sources and disposal of low level radioactive hospital waste) is EUR 5 million.

With sales of EUR 14.8 million and an EBIT of EUR 2.4 million, the Therapy segment achieved a very good result in the first half of the year. Compared to halved figures excluding special effects for the previous year, the 2010 figures amount to a 2% sales decrease and an 11% increase in the EBIT. The reduced minority interests had a significant positive effect after the takeover bid. In the second quarter of 2009, these still amounted to 59%, while in the second quarter of 2010, minority shareholders of IBt. S.A. only accounted for 28% of the revenue after tax. For detailed information about the Therapy segment, refer to the IBt S.A. quarterly report, which is published at the same time. In the profit and loss statement, there are minor shifts and valuation differences between the Eckert & Ziegler and the IBt financial statements, which are listed in the following table.

Milestones

II/2010

- Through its Belgian subsidiary IBt Bebig, Eckert & Ziegler receives a major order from France for the delivery of medical technology for treating prostate cancer.
- IBt Bebig publishes first results of a radiobiological research program according to which brachytherapy with permanent implants can be used for the monotherapy of early-stage breast cancer.
- The subsidiary Eckert & Ziegler f-con Deutschland GmbH wins a tender for the regular delivery of radiodiagnostics to the medical university in Danzig, Poland with a volume of approx. EUR 1.3 million.
- The American subsidiary Eckert & Ziegler Isotope Products Inc. receives a certificate of recognition as “good corporate citizens” for the year 2009 from the Sanitation Districts of Los Angeles County for complying consistently with all their industrial wastewater discharge requirements.
- Braunschweig-based Eckert & Ziegler Nuclitec becomes the main supplier of the radioactive component for the ZEVALIN® cancer drug of the American drug manufacturer Spectrum Pharmaceuticals Inc.

	Therapy Segment EZAG	IBt semi-annual report	Difference	Of which customer base amortization	Of which loss carryforward	Of which stock options
Revenues	14,916	14,916				
Costs	-12,724	-12,452	-272	-174		-98
EBT	2,192	2,464	-272	-174		-98
Income tax expense	-815	-792	-23	52	-75	
Net income	1,377	1,672	-295	-122	-75	-98
Profit/loss attributable to minority interests	-470					
Dividend to shareholders of Eckert & Ziegler AG	907					

Compared to the first half of 2009, the Radiopharma segment managed to increase sales by 3% to EUR 10.0 million while keeping costs almost constant. In addition, there was extraordinary revenue of several hundred thousand euros from transfers of shares and borrowing of Eckert & Ziegler EURO-PET Berlin GmbH. Overall, the EBIT increased from EUR 0.5 million to EUR 1.1 million.


We have seen the emergence of a trend across all segments in which revenues have continued to rise sharply even as the pace of growth in sales volume has slowed significantly.

The brief segment statistics (in thousands of euros) on the next page illustrate the sources of sales and revenue.


Liquidity

For the first half of 2010, the cash flow statement shows a P&L cash result of EUR 9.7 million, which exceeds the corresponding previous year's value by 4%. In contrast to 2009, however, net current assets increased by EUR 4.1 million, so that cash inflow from operating activities of only EUR 5.6 million remains. In 2010, the investments contain the payments for the purchase of additional IBt shares for EUR 22.5 million. The previous year included the purchase price of EUR 4.5 million for Nuclitec. The other investments amounted to EUR 2.4 million compared to the EUR 3.0 million in the same period in the previous year. In May, 37% of the purchase price paid for the additional IBT shares in April was refinanced by means of a long-term loan of

External sales (in TEUR)



Profit after taxes (in TEUR)



* formerly called: "Industry" segment

Brief segment overview

		Therapy	Isotope Products*	Radiopharma	Environmental Services	Other	Total	Isotope Products + Environmental Services
External sales	1-6, 2010	14,769	25,483	9,980	2,652	0	52,884	28,135
	Avg. 1-6, 2009	15,139	25,872	9,689		0	50,700	25,872
Profit after taxes	1-6, 2010	1,377	4,883	276	-117	-560	5,859	4,766
	Avg. 1-6, 2009 without special effects	1,068	2,898	-37		458	4,387	2,898
Return on sales %	1-6, 2010	9%	19%	3%	-4%		11%	17%
	Avg. 1-6 2009 without special effects	7%	11%	0%			9%	11%
Sales growth	absolute	-370	-389	+292			+2,185	+2,263
	in %	-2%	-2%	+3%			+4%	+9%
Profit growth	absolute	+309	+1,986	+313		-1,018	+1,472	+1,869
	in %	+29%	+69%				+34%	+64%

* formerly called: "Industry" segment

EUR 8.25 million. In the first half of 2010, loan repayments amounted to EUR 2.5 million. In addition to that, the EUR 2.3 million dividend paid in May was more than twice as high as the previous year's. Overall, cash and cash equivalents were reduced by EUR 14.5 million compared to December 31, 2009 and amounted to EUR 29.2 million on June 30, 2010.

Balance sheet

The IBt takeover bid has major effects on the balance sheet. Since IBt has already been consolidated since the first quarter of 2008, there is no change on the asset side of the consolidated balance sheet in accordance with IFRS 3 (2008). Instead, the offsetting posting for the payout of approx. EUR 22.5 million is made in the equity: On the one hand, the acceptance quote of 55% halves the minority interests from EUR 10 million to EUR

5 million. On the other hand, retained earnings are summarily reduced in accordance with IFRS.

After the shareholders' equity ratio was again above 50% following the capital increase and the very good annual results for December 31, 2009, the ratio of shareholders' equity to total assets fell to 48% on June 30, 2010. After the negative effects of the posting of the IBt takeover bid, the dividend paid in May 2010 also reduced the equity ratio.

The loan of USD 2.0 million granted to Core Oncology at the end of the year 2009 was due for repayment on June 30, 2010. Interest payments made in the meantime were made according to the contract. The scheduled repayment, however, has been postponed with the effect that the loan granted was restructured from short-term to long-term receivables.

Research and development

In the Therapy segment, work on developing a complete system for manufacturing prostate cancer implants for Russia is entering the final phase. After the already delivered packaging system and the accepted system for producing seed chains, additional components for the seed production line were set up in the Berlin test lab and entered into non-production operation. For the tumor irradiation equipment of the MultiSource® type, a new, more user-friendly software version for clinical users was launched on the market.

A new version of the best-selling "Featherlite" flood source used for medical imaging was developed in the Isotope Products segment. The new product was presented for the first time at the Annual Congress of the German Association of Nuclear Medicine.

Staff

As of June 30, 2010, the Eckert & Ziegler Group had 357 employees in Germany, and a total of 534 employees worldwide. Compared with the end of 2009, the number of staff increased by 8 (December 31, 2009: 526). This change mainly affects the Isotope Products segment. The number of staff at the sites in the USA and the Czech Republic increased by 5.

Outlook

For the financial year 2010, the target for sales is EUR 105 million. The Executive Board is keeping its profit forecast at EUR 9.5 million (EUR 1.80 per share). This goal can be achieved from the operating business without acquisitions, assuming the US dollar/euro exchange rate stays within its range of the last few months so that the annual average for 2010 does not exceed the exchange rate benchmark of USD 1.34 per euro shown for the half-year.

Group Statement of Income	Quarterly Report II/2010 04 - 06/2010	Quarterly Report II/2009 04 - 06/2009	6-monthly Report 01 - 06/2010	6-monthly Report 01 - 06/2009
	TEUR	TEUR	TEUR	TEUR
Revenues	27,182	28,041	52,884	52,353
Cost of sales	-12,962	-13,013	-24,574	-24,744
Gross profit on sales	14,220	15,028	28,310	27,609
Selling expenses	-5,185	-5,220	-9,442	-9,948
General and administrative expenses	-4,493	-5,216	-9,253	-9,509
Research and non-capitalized development expenses	-455	-447	-1,034	-943
Other operating income	336	341	1,045	673
Other operating expenses	-31	-178	-248	-227
Profit from operations	4,392	4,308	9,378	7,655
Earnings from shareholdings accounted for using the equity method			-	-
Other financial results	436	-185	638	193
Earnings before interest and taxes (EBIT)	4,828	4,123	10,016	7,848
Interest received	67	9	123	30
Interest paid	-285	-356	-718	-723
Profit before tax	4,610	3,776	9,421	7,155
Income tax expense	-1,567	-641	-3,562	-1,344
Profit from continuing operations	3,043	3,135	5,859	5,811
Profit from discontinued operations, net	-	-	-	97
Net income	3,043	3,135	5,859	5,908
Profit/loss attributable to minority interests	-432	-1,327	-732	-1,943
Dividend to shareholders of Eckert & Ziegler AG	2,611	1,808	5,127	3,965
Earnings per share				
Basic	0.50	0.48	0.99	1.08
Diluted	0.50	0.48	0.98	1.08
Average number of shares in circulation (basic)	5,190	3,770	5,194	3,658
Average number of shares in circulation (diluted)	5,201	3,787	5,216	3,670

Group Statement of Comprehensive Income	Quarterly Report II/2010 04-06/2010	Quarterly Report II/2009 04-06/2009	6-monthly Report 01-06/2010	6-monthly Report 01-06/2009
	TEUR	TEUR	TEUR	TEUR
Profit for the period	3,043	3,135	5,859	5,908
Of which attributable to other shareholders (loss in previous year)	432	1,327	732	1,943
Of which attributable to shareholders of Eckert & Ziegler AG	2,611	1,808	5,127	3,965
Adjustment to fair value of available-for-sale financial assets	1	-12	3	5
Amount reposed to income statement	0	0	0	0
Profit tax	0	3	-1	-2
Adjustment of amount recorded in shareholders' equity (Financial assets available-for-sale)	1	-9	2	3
Adjustment of balancing item from the currency translation of foreign subsidiaries	1,663	-729	2,684	-56
Amount reposed to income statement	0	0	0	0
Adjustment of amount recorded in shareholders' equity (Currency translation)	1,663	-729	2,684	-56
Total of value adjustments recorded in shareholder equity	1,664	-738	2,686	-53
Of which attributable to other shareholders	-10	0	20	0
Of which attributable to shareholders of Eckert & Ziegler AG	1,674	-738	2,666	-53
Total from net income and value adjustments recorded in shareholder equity	4,707	2,397	8,545	5,855
Of which attributable to other shareholders	422	1,327	752	1,943
Of which attributable to shareholders of Eckert & Ziegler AG	4,285	1,070	7,793	3,912

Group Statement of Cash Flows	6-monthly Report 01 - 06/2010	6-monthly Report 01 - 06/2009
	TEUR	TEUR
Cash flows from operating activities:		
Profit for the period	5,859	5,908
Adjustments for:		
Depreciation	3,871	3,484
Proceeds from grants less release of deferred income from grants	-133	47
Deferred tax	293	-276
Unrealized foreign currency gains/losses	-204	-31
Long-term provisions, other non-current liabilities	384	182
Gains (-)/losses on the disposal of non-current assets	-4	14
Other	-334	-1
Changes in current assets and liabilities:		
Receivables	-1,713	-1,589
Inventories	958	384
Prepaid expenses and deferred charges, other current assets	-57	-102
Trade accounts payable and accounts payable to related parties	-2,844	-1,656
Income tax liabilities	918	-545
Other liabilities	-1,410	702
Cash inflows generated from operating activities	5,584	6,521
Cash flows from investment activities:		
Purchase (-)/sale of non-current assets	-2,363	-3,009
Acquisition of shares of consolidated companies	-22,539	-4,467
Purchase (-)/sale of shareholdings	-	28
Purchase (-)/sale of securities	-	101
Cash outflows from investment activity	-24,902	-7,347
Cash flows from financing activities:		
Dividends paid	-2,335	-1,132
Cash inflow from capital increase	-	3,079
Change in long-term borrowings	6,191	5,053
Change in short-term borrowings	-426	-1,674
Distribution to minority interests	-59	-
Acquisition of own shares	-	-136
Sale of own shares or own shares used for share option plans	712	6
Cash inflow from financing activities	4,083	5,196
Effect of exchange rates on cash and cash equivalents	722	23
Increase/reduction in cash and cash equivalents	-14,513	4,393
Cash and cash equivalents at beginning of period	43,674	7,311
Cash and cash equivalents at end of period	29,161	11,704

Group Balance Sheets	June 30, 2010	Dec, 31, 2009
	TEUR	TEUR
ASSETS		
Non-current assets		
Intangible assets	43,312	42,123
Property, plant and equipment	27,635	27,253
Investments valued according to the equity method	517	850
Deferred tax	11,460	11,795
Other non-current assets	2,027	910
Total non-current assets	84,951	82,931
Current assets		
Cash and cash equivalents	29,161	43,674
Securities	228	226
Trade accounts receivable	18,097	16,204
Inventories	12,693	12,631
Other current assets	2,769	6,238
Total current assets	62,948	78,973
Total assets	147,899	161,904
EQUITY AND LIABILITIES		
Capital and reserves		
Subscribed capital	5,293	5,260
Capital reserves	52,621	52,719
Retained earnings	9,472	22,514
Other reserves	-720	-3,385
Own shares	-401	-703
Share in equity attributable to the shareholders of Eckert & Ziegler AG	66,265	76,405
Minority interests	5,463	10,254
Total shareholders' equity	71,728	86,659
Non-current debts		
Long-term borrowings and finance lease obligations	19,594	14,262
Deferred income from grants and other deferred income	1,248	1,384
Deferred tax	1,724	1,627
Retirement benefit obligations	6,026	5,707
Other provisions	17,892	17,589
Other non-current liabilities	724	678
Total non-current debts	47,208	41,247
Current debts		
Short-term borrowings and finance lease obligations	5,685	5,813
Trade accounts payable	4,142	4,426
Advance payments received	5,598	8,005
Deferred income from grants and other deferred income	384	395
Current tax payable	940	943
Other current liabilities	12,214	14,416
Total current debts	28,963	33,998
Total equity and liabilities	147,899	161,904

	Subscribed capital		Capital reserve	Retained reserves	Cumulative other equity items			Own shares	Equity attributable to shareholders' equity	Minority shares	Group shareholders' equity
	Number	Nominal value			Unrealized profit securities	Unrealized profit pension commitments	Foreign currency exchange differences				
	TEUR	TEUR			TEUR	TEUR	TEUR				
As of January 1, 2009	3,250,000	3,250	30,316	10,946	7	0	-3,304	-359	40,856	1,964	42,820
Foreign currency translation differences							64		64	-8	56
Unrealized gains/losses on performance-orientated pension commitments at balance sheet date (after tax of EUR -69 thousand)					0	-149			-149		-149
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 2 thousand)					4				4		4
Reversal of unrealized gains/losses on securities at previous balance sheet date					-7				-7		-7
Total of expenditures and income directly entered in equity	0	0	0	0	-3	-149	64	0	-88	-8	-96
Net profit for the year				13,250					13,250	8,642	21,892
Total income for the period	0	0	0	13,250	-3	-149	64	0	13,162	8,634	21,796
Dividends paid				-1,132					-1,132	-409	-1,541
Purchase or sale of minority interests			-507						-507	65	-442
Application of own shares for acquisitions and to service share options			-4	4				6	6		6
Acquisition of own shares			436	-436				-436	-436		-436
Sale of own shares			118	-118				86	86		86
Capital increase	2,010,283	2,010	22,360						24,371		24,371
As of December 31, 2009	5,260,283	5,260	52,719	22,514	4	-149	-3,240	-703	76,405	10,254	86,659
	Subscribed capital		Capital reserve	Retained reserves	Cumulative other equity items			Own shares	Equity attributable to shareholders' equity	Minority shares	Group shareholders' equity
	Number	Nominal value			Unrealized profit securities	Unrealized profit pension commitments	Foreign currency exchange differences				
	TEUR	TEUR			TEUR	TEUR	TEUR				
As of January 1, 2010	5,260,283	5,260	52,719	22,514	4	-149	-3,240	-703	76,405	10,254	86,659
Foreign currency translation differences							2,664		2,664	20	2,684
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 3 thousand)					6				6		6
Reversal of unrealized gains/losses on securities at previous balance sheet date					-4				-4		-4
Total of expenditures and income directly entered in equity	0	0	0	0	2	0	2,664	0	2,666	20	2,686
Net profit for the year				5,127					5,127	732	5,859
Total income for the period	0	0	0	5,127	2	0	2,664	0	7,793	752	8,545
Dividends paid				-2,335					-2,335	-58	-2,393
Purchase or sale of minority interests				-17,082					-17,082	-5,485	-22,567
Application of own shares for loan acquisitions and to service share options			-189	772				189	772		772
Sale of own shares			-113	476				113	476		476
Capital increase authorized but unissued share capital	32,700	33	204						237		237
As of June 30, 2010	5,292,983	5,293	52,621	9,472	6	-149	-576	-401	66,265	5,463	71,728

	Isotope Products*		Therapy		Radiopharma		Environmental Services		Other		Elimination		Total	
	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	25,483	26,335	14,769	16,318	9,980	9,700	2,652	-	0	0	0	0	52,884	52,353
Sales to other segments	470	232	147	175	11	10	86	-	504	504	-1,218	-921	0	0
Total segmental sales	25,953	26,567	14,916	16,493	9,991	9,710	2,738	-	504	504	-1,218	-921	52,884	52,353
Segment profit before interest and profit taxes (EBIT)	7,447	5,077	2,364	3,131	1,074	654	-38	-	-833	-1,011	2	-3	10,016	7,848
Interest expenditures and revenues	-192	-294	-172	-311	-488	-488	-24	-	283	397	-2	3	-595	-693
Income tax expense	-2,372	-1,555	-815	33	-310	-5	-55	-	-10	183			-3,562	-1,344
Profit before minority interests	4,883	3,228	1,377	2,853	276	161	-117	-	-560	-431			5,859	5,811

* formerly called: "Industry" segment

	Isotope Products		Therapy		Radiopharma		Environmental Services		Other		Total	
	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009	1-6 2010	1-6 2009
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Segmental assets	67,258	60,313	55,964	46,344	16,710	17,899	**	-	105,801	75,537	245,733	200,093
Elimination of inter-segmental shares, equity investments and receivables											-97,834	-75,560
Consolidated total assets											147,899	124,533
Segmental liabilities	-33,163	-33,378	-25,776	-22,012	-19,754	-20,547	**	-	-25,409	-24,989	-104,102	-100,926
Elimination of inter-segmental liabilities											27,931	26,505
Consolidated liabilities											-76,171	-74,421
Investments	589	710	994	977	675	1,322	101	-	4	1	2,363	3,010
Depreciation	-1,155	-1,103	-1,445	-1,316	-959	-967	-223	-	-89	-98	-3,871	-3,484
Non-cash income/expenses	-18	-41	-424	78	309	-137	0	-	131	167	-2	67

** In internal reporting, the asset and liability items of the Environmental Services segment are still shown in the Isotope Products segment. For this reason, the numbers are shown in the same way in the segment reporting.

Sales by region	January - June 2010		January - June 2009	
	Million EUR	%	Million EUR	%
Europe	31.9	60	32.0	61
North America	15.4	30	14.7	28
Asia/Pacific	4.9	9	5.3	10
Other	0.7	1	0.4	1
Total	52.9	100	52.4	100

1. General information

These unaudited interim consolidated financial statements as of June 30, 2010, comprise the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (also referred to hereinafter as "Eckert & Ziegler AG").

2. Accounting and valuation methods

The consolidated financial statements (interim financial statements) of Eckert & Ziegler AG as of June 30, 2010, have been prepared, like the annual financial statements for 2009, in accordance with the International Financial Reporting Standards (IFRS). All of the standards of the London-based International Accounting Standards Board (IASB) which were applicable in the EU on the balance sheet date, as well as the relevant interpretations of the International Financial Reporting Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC), have been observed. The accounting policies described in the appendix to the annual financial statements for 2009 have been applied unchanged. For the preparation of the consolidated financial statements in compliance with the IFRS, it is necessary for estimates and assumptions to be made that have an impact on the amount and disclosure of recognized asset values and liabilities, income and expenditures. The actual values may differ from the estimates. Significant assumptions and estimates are made concerning useful lives, earnings attainable from goodwill and non-current assets, the realizability of receivables, and the recognition and measurement of provisions. This interim report contains all of the necessary information and adjustments required to produce a picture which reflects the actual circumstances in respect to the assets, financial situation and earnings position of Eckert & Ziegler AG at the time the interim report was produced. The earnings achieved during the course of the current fiscal year do not necessarily allow conclusions to be drawn about the development of future earnings.

3. Companies included in the consolidation

In the consolidated financial statements of Eckert & Ziegler AG, all companies are included where Eckert & Ziegler AG, either indirectly or directly, is able to determine the financial and business policies (control concept).

Company acquisitions and disposals

Regarding acquisitions and disposals, please refer to the notes under section 4.

4. Limited comparability of group financial statements with the previous year

In January 2009, shares were bought in the companies nuclitec GmbH, nuclitec sarl and nuclitec Inc. In March 2010, the takeover bid for the shares of IBt S.A. that were not in possession of Eckert & Ziegler AG ended, whereupon Eckert & Ziegler increased its holdings in the IBt shares eligible for dividends to 72%. In March 2010, the Eckert & Ziegler Group increased its stake in Eckert & Ziegler EURO-PET Berlin GmbH from 70% to 100%. In March 2010, the Eckert & Ziegler Group increased its stake in Eckert & Ziegler f-con Europe GmbH from 74% to 77%. Compared with the first six months of 2009, this has impacted substantially on the financial situation and earnings position of the Group, which means that it is difficult to compare the Group report with the previous year's report.

5. Currency translation

The financial statements for the companies outside the European Monetary Union are translated based on the concept of functional currency. The following exchange rates were used for the currency translation: Refer to the table below.

6. Portfolio of own shares

As of June 30, 2010, Eckert & Ziegler AG held 71,485 own shares. This equates to a share of 1.4% of the Company's nominal capital.

Country	Currency	Exchange rate on June 30, 2010	Exchange rate on Dec. 31, 2009	Average rate Jan. 1 – June 30, 2010	Average rate Jan. 1 – June 30, 2009
USA	USD	1.2208	1.4330	1.3367	1.3384
Czech Republic	CZK	25.7921	26.4215	25.7743	27.3813
Great Britain	GBP	0.8103	0.9000	0.8674	0.8955
Sweden	SEK	9.5299	10.2603	9.8077	10.9537

7. Substantial transactions with affiliated persons

In respect to substantial transactions with affiliated persons, we refer to the publications made in the consolidated financial statements dated December 31, 2009.

8. Declaration in accordance with § 37y of the Securities Trading Act in conjunction with § 37w para. 2 no. 3 of the Securities Trading Act

To the best of our knowledge, we provide an assurance that, in accordance with the applied principles of proper interim financial results reporting, the consolidated interim financial statements give a true and fair picture of the assets, financial position and earnings position of the Group, that the interim Group management report outlines the development and performance of the business and the position of the Group, that a picture which reflects the actual circumstances is conveyed and that the principal opportunities and risks associated with the expected development of the Group in the rest of the fiscal year are described.

Berlin, Germany, August 3, 2010



Dr. Andreas Eckert
Chief Executive Officer



Dr. Edgar Löffler
Executive Board Member



Dr. André Heß
Executive Board Member

Financial Calendar

November 02, 2010

Quarterly Report III/2010

November 24, 2010

German Equity Forum in Frankfurt

March 30, 2011

Annual Report 2010

March 30, 2011

Balance Press Conference in Berlin

May 03, 2011

Quarterly Report I/2011

May 2011

Entry and General Standard Conference in Frankfurt

May 19, 2011

Annual General Meeting in Berlin

August 02, 2011

Quarterly Report II/2011

November 02, 2011

Quarterly Report III/2011

November 2011

German Equity Forum in Frankfurt

Contact

Eckert & Ziegler
Strahlen- und Medizintechnik AG

Karolin Riehle
Investor Relations

Robert-Rössle-Str. 10
13125 Berlin
www.ezag.de

Telephone +49 (0) 30 94 10 84 - 0
Telefax +49 (0) 30 94 10 84 - 112
E-Mail karolin.riehle@ezag.de

ISIN DE0005659700
WKN 565970